ID   NCCIT-R
AC   CVCL_C0QL
DR   cancercelllines; CVCL_C0QL
DR   PRIDE; PXD030251
DR   Wikidata; Q112930165
RX   PubMed=35084545;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Lys309Asn (c.927G>C); Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Pro (c.518G>C); ClinVar=VCV000185195; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Cysfs*73 (c.814delG); Zygosity=Homozygous (from parent cell line).
CC   Omics: Deep quantitative proteome analysis.
DI   NCIt; C6341; Testicular embryonal carcinoma
DI   ORDO; Orphanet_289362; Non-central nervous system-localized embryonal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1451 ! NCC-IT
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 4
//
RX   PubMed=35084545; DOI=10.1007/s00345-022-03936-1;
RA   Fichtner A., Bohnenberger H., Elakad O., Richter A., Lenz C., Oing C.,
RA   Strobel P., Kueffer S., Nettersheim D., Bremmer F.;
RT   "Proteomic profiling of cisplatin-resistant and cisplatin-sensitive
RT   germ cell tumour cell lines using quantitative mass spectrometry.";
RL   World J. Urol. 40:373-383(2022).
//